Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma

Bone Marrow Transplantation volume 39, pages 605–611 (2007)Cite this article

Abstract

High-dose chemotherapy with stem cell transplantation (SCT) is feasible for elderly patients and patients with renal insufficiency. However, the impact of treatment on this patient population is unclear. We evaluated 678 consecutive patients with multiple myeloma who underwent SCT at Mayo Clinic. The complete response rate, time to progression and overall survival was recorded. Patients were stratified according to age (⩽65 or >65 years) and serum creatinine value at the time of transplantation (⩽2 or >2 mg/dl). Patient age did not have an effect on any outcome measure. Creatinine level did not affect complete response rate and time to progression, but patients with creatinine levels above 2 mg/ml had a higher day-100 mortality rate and a shorter overall survival rate. Platelet engraftment was also significantly delayed for patients with renal insufficiency. Selected patients over age 65 years may have outcomes identical to that of younger patients. When compared with patients with creatinine levels less than 2 mg/ml, patients with elevated creatinine levels had similar response rates and time to progression, but their overall survival was inferior. Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al., Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al., Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  3. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057 [E-pub 2004 Jul 20].

    Article  CAS  Google Scholar 

  4. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al., Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233 [E-pub 2005 Nov 7].

    Article  CAS  Google Scholar 

  5. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Renaud M et al. Major superiority of melphalan–prednisone (MP)+thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (abstract). Blood 2005; 106: 230a.

    Google Scholar 

  6. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al., Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  7. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA . Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  PubMed  Google Scholar 

  8. Durie BG, Salmon SE . A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.

    Article  CAS  Google Scholar 

  9. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420 [E-pub 2005 April 4. Erratum in: J Clin Oncol 2005;23:6281].

    Article  Google Scholar 

  10. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539.

    Article  CAS  Google Scholar 

  11. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  Google Scholar 

  12. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  Google Scholar 

  13. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age. Bone Marrow Transplant 2003; 32: 1135–1143.

    Article  CAS  Google Scholar 

  14. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  Google Scholar 

  15. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  Google Scholar 

  16. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  Google Scholar 

  17. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  Google Scholar 

  18. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28–36.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Editing, proofreading and reference verification were provided by the Section of Scientific Publications, Mayo Clinic.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    M A Gertz, M Q Lacy, A Dispenzieri, S R Hayman, S Kumar & D A Gastineau

  2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    N Leung

Authors
  1. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S R Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D A Gastineau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M., Lacy, M., Dispenzieri, A. et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 39, 605–611 (2007). https://doi.org/10.1038/sj.bmt.1705627

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705627

Keywords

This article is cited by

Search

Advanced search

Quick links